NeoPharm (NEOL) Begins Enrollment for Phase II Trial of Liposomal Paclitaxel
NeoPharm, Inc. (NASDAQ: NEOL) has enrolled its first patients in its multi-center open-label, Phase II clinical trial of Liposomal Paclitaxel (LEP-ETU) for efficacy and safety in patients with Metastatic Breast Cancer. In pre-clinical and Phase I clinical data, LEP-ETU demonstrated a reduced side-effect profile, particularly peripheral neuropathy, as well as the potential for increased dosage and greater efficacy over Taxol(R), the standard care for many tumors, principally breast and ovarian cancer.
NeoPharm has developed this liposomal formulation of paclitaxel in an effort to improve the safety profile of the currently marketed paclitaxel formulations by eliminating other toxic excipients, such as Cremophor(R) and ethanol, which must be co-administered to help decrease unwanted side effects.[SM]
Create E-mail AlertRelated Categories
Corporate NewsStocks Mentioned
+1.50Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
